BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32932783)

  • 1. Evaluation of a New
    Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new
    Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M
    EJNMMI Res; 2020 Aug; 10(1):90. PubMed ID: 32757150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
    Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
    Cescato R; Waser B; Fani M; Reubi JC
    J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, preparation and biological evaluation of a
    Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
    Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
    Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA
    J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
    Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
    Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
    Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
    Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
    Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.